NKTR Nektar Therapeutics

20.79
-0.71  -3%
Previous Close 21.50
Open 21.49
Price To book 74.39
Market Cap 3.23B
Shares 155,149,000
Volume 1,523,060
Short Ratio 5.79
Av. Daily Volume 2,208,760

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 1H 2017.
Cipro DPI
Bronchiectasis
Phase 3 data released March 20, 2017 - endpoints met.
NKTR-181
Lower back pain
Phase 1/2 initial data due at ASCO investor event June 3, 2017. Abstract 2545 (June 5 poster).
NKTR-214
Solid tumors - cancer
Phase 3 data due mid-2017.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
ADYNOVATE
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 3 data released December 12, 2016 - primary endpoint not met.
Fovista
Wet-AMD

Latest News

  1. New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds
  2. Bristol-Incyte Match Beats Dow's Merck In Combination Trials
  3. Nektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : May 18, 2017
  4. Nektar Therapeutics Announces Data Presentations at ASCO 2017
  5. Edited Transcript of NKTR earnings conference call or presentation 9-May-17 9:00pm GMT
  6. ETFs with exposure to Nektar Therapeutics : May 15, 2017
  7. Nektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York
  8. Nektar Therapeutics :NKTR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  9. Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1
  10. The Not-So-Subtle Reason Behind Nektar Therapeutics' 10% Pop
  11. Nektar reports 1Q loss
  12. Nektar Therapeutics Reports Financial Results for the First Quarter of 2017
  13. Investor Network: Nektar Therapeutics to Host Earnings Call
  14. Nektar Therapeutics – Value Analysis (NASDAQ:NKTR) : May 8, 2017
  15. Why Nektar Therapeutics Shares Fell 19.2% in April
  16. Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : May 5, 2017
  17. Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program
  18. Nektar to Announce Financial Results for the First Quarter of 2017 on Tuesday, May 9, 2017, After Close of U.S.-Based Financial Markets
  19. Biotech Surge: How To Survive In A Volatile Market
  20. Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting

SEC Filings

  1. 8-K - Current report 17858269
  2. SD - 17845622
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828138
  4. 8-K - Current report 17826908
  5. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17800474
  6. DEF 14A - Other definitive proxy statements 17800422
  7. 8-K - Current report 17743479
  8. 8-K - Current report 17700075
  9. 8-K - Current report 17654654
  10. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17653530